$MPLT News

Needham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43

MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics Launching $150 Million Private Placement Financing

MapLight Therapeutics Announces $150 Million Private Placement Financing

MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement Financing

UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13

MapLight Therapeutics stock crashes on Phase II schizophrenia data

Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24

Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21

MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia Transcript

HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26

MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia - Slideshow

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose

Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint

MapLight Therapeutics' Lead Candidate Falls Meaningfully Short In Schizophrenia

MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

Maplight Therapeutics Says Phase 2 Zephyr Trial Of ML-007C-MA For Acute Exacerbation Of Schizophrenia Met Its Primary Endpoint, With 210/3 Mg Twice-Daily Dose, While 330/6 mg Once-daily Dose Missed Primary Endpoint

Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56?

UBS Maintains Buy on MapLight Therapeutics, Raises Price Target to $52